Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo ketoester drop pills for vertigo caused by cerebral arteriosclerosis
ChiCTR1900020572Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Jan 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ginkgo ketoester in cerebral arteriosclerosis and vertigo (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Change of the TCM syndrome. Started Jan 2019; status: recruiting.
02
Drugs
ginkgo ketoester
03
Conditions
cerebral arteriosclerosisvertigo
Beyond the preview
Go deeper on ChiCTR1900020572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020572.